19. Allergan by Kyle Blankenship Irish drugmaker Allergan scored a major coup in 2019, courtesy of a $63 billion buyout offer from AbbVie. In return, Allergan will be bringing over longtime blockbuster Botox.
Allergan targets millennials with new Juvederm lip campaign by Beth Snyder Bulik Tuesday, February 11, 2020 Allergan’s latest Juvederm effort focuses on lips as the company targets millennials, who tend to join the facial aesthetic market by trying fillers.
AbbVie answers Allergan aesthetics worries with new unit by Kyle Blankenship Wednesday, January 8, 2020 AbbVie has an answer to worries Allergan's aesthetics business will drag on its bottom line: Just keep the business separate.
AbbVie-Allergan could look to asset sales to offset Humira loss by Kyle Blankenship Tuesday, January 7, 2020 Allergan's best-selling Botox and other promising meds may not be enough to fill the Humira gap. What could help? Hiving off assets, one analyst says.
Allergan amps aesthetics advertising by Beth Snyder Bulik Monday, September 24, 2018 Allergan plans to double its investment in consumer advertising, grow its sales force by 20%, and launch one to two new aesthetic products every year.
The world's best pharma market? Easy one, Allergan CEO says by Carly Helfand Monday, August 7, 2017 What’s the best pharma market in the world? According to Allergan CEO Brent Saunders, it’s medical aesthetics.
